Avinger Appoints Jaafer Golzar, MD, FACC, FSCAI, as Chief Medical Officer
July 10 2018 - 8:30AM
Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative
treatments for peripheral artery disease (PAD), today announced the
appointment, effective immediately, of Jaafer Golzar, MD, as the
Company’s Chief Medical Officer. Dr. Golzar provides Avinger with
an extensive and impressive history of clinical leadership within
the endovascular field.
Dr. Golzar is a practicing interventional cardiologist with
Advocate Medical Group in Chicago. He is the Director of Limb
Salvage and Endovascular Intervention at Advocate Trinity Hospital.
Dr. Golzar is also a leading educator on interventional techniques
and technologies and is the founder and previous director of the
Chicago Endovascular Conference (CVC), an international-scale
annual conference designed to address the educational needs of
physicians and other health care professionals treating patients
with peripheral arterial and venous diseases. Prior to joining
Avinger, Dr. Golzar was also Medical Director – Interventional
Vascular for BTG International. He has participated in multiple
clinical research trials, including studies of PAD treatment with
atherectomy, drug-eluting balloons and stents and has authored
numerous publications in peer-reviewed journals. As a recognized
leader in the endovascular community, Dr. Golzar has received
multiple accolades including the prestigious Pioneers in
Performance - North America Award in 2014. He is a Fellow of the
American College of Cardiology and of the Society for
Cardiovascular Angiography and Interventions. Dr. Golzar will
maintain a part-time clinical practice while he serves as Avinger’s
Chief Medical Officer.
“We are extremely pleased that Dr. Golzar has joined our
executive leadership team and are confident he will provide
valuable clinical and strategic perspective to our company,” said
Jeff Soinski, president and CEO of Avinger. “His feedback on
earlier versions of Avinger’s Lumivascular technology led to many
of the enhancements designed into our recently-launched
next-generation Pantheris, and we anticipate his clinical acumen
will contribute substantially to Avinger’s future product
development and clinical study initiatives. Furthermore, Dr.
Golzar’s relationships and respect within the PAD treatment
community and among potential strategic partners will meaningfully
and positively impact the adoption of Lumivascular and the value of
our Company.”
Jaafer Golzar, MD, commented, “Having worked with all the major
tools used to treat peripheral disease, there is no technology I’m
more excited about than Avinger’s Lumivascular platform. I am
particularly impressed with the recent advances in the
next-generation Pantheris, and I look forward to spreading the word
about its benefits with my fellow interventionists, as well as
working with the Avinger team to develop additional products that
leverage the unique benefits of real-time intravascular
visualization provided by the Lumivascular platform. Being a part
of such groundbreaking technologies that improve safety and
outcomes for patients is what continues to drive my passion for the
cardiac and endovascular medical field.”
About Avinger, Inc. Avinger is a
commercial-stage medical device company that designs and develops
the first-ever image-guided, catheter-based system that diagnoses
and treats patients with peripheral artery disease (PAD). Avinger
is dedicated to radically changing the way vascular disease is
treated through its Lumivascular platform, which currently consists
of the Lightbox imaging console, the Ocelot family of chronic total
occlusion (CTO) catheters, and the Pantheris® family of
atherectomy devices. Avinger is based in Redwood City, CA. For more
information, please visit www.avinger.com.
Forward-Looking Statements This news release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934 and the Private Securities Litigation Reform
Act of 1995. These forward-looking statements include statements
regarding Dr. Golzar’s future professional activities and
contributions to Avinger’s business, anticipated adoption of
Lumivascular technology, product development and clinical study
initiatives and growth of Avinger’s business. Such statements are
based on current assumptions that involve risks and uncertainties
that could cause actual outcomes and results to differ materially.
These risks and uncertainties, many of which are beyond our
control, include our dependency on a limited number of products;
our ability to demonstrate the benefits of our Lumivascular
platform; the resource requirements related to Pantheris; the
outcome of clinical trial results; potential exposure to
third-party product liability, intellectual property and other
litigation; lack of long-term data demonstrating the safety and
efficacy of our Lumivascular platform products; experiences of
high-volume users of our products may lead to better patient
outcomes than those of physicians that are less proficient;
reliance on third-party vendors; dependency on physician adoption;
reliance on key personnel; and requirements to obtain regulatory
approval to commercialize our products; as well as the other risks
described in the section entitled “Risk Factors” and elsewhere in
our quarterly report on Form 10-Q filed with the Securities and
Exchange Commission on May 15, 2018. These forward-looking
statements speak only as of the date hereof and should not be
unduly relied upon. Avinger disclaims any obligation to update
these forward-looking statements.
Public Relations Contact: Phil Preuss VP of
Marketing & Business Operations Avinger, Inc. (650) 241-7900
pr@avinger.com
Investor Contact: Mark Weinswig Chief Financial
Officer Avinger, Inc. (650) 241-7916 ir@avinger.com
Avinger (NASDAQ:AVGR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Avinger (NASDAQ:AVGR)
Historical Stock Chart
From Sep 2023 to Sep 2024